-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IInDueDtGl+4p2DkrIrWz/AgOXPUUSOtHdTjYWhXWVdh6TjNDiZxD2by/Y+q0Pky foKcvTUXj0IOk4xmjGAsnQ== 0001144204-04-007984.txt : 20040603 0001144204-04-007984.hdr.sgml : 20040603 20040603131857 ACCESSION NUMBER: 0001144204-04-007984 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20040603 ITEM INFORMATION: Other events FILED AS OF DATE: 20040603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 04846552 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 form8k.htm Unassociated Document
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 3, 2004
Date of Report
(Date of earliest event reported)


RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-30959

 94-3199149

(Commission File Number)

(I.R.S. Employer Identification No.)


967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)


 
     
 

Item 5. Other Events and Required FD Disclosure.

On June 3, 2004, RITA Medical Systems, Inc., a Delaware corporation, announced it will provide WebMD Medscape Health Network an unrestricted educational grant to support a live online continuing medical education program to teach medical oncologists and interventional radiologists about the use of radiofrequency ablation treatment for soft tissue cancer tumors. A copy of the joint press release announcing this release is attached as Exhibit 99.1 hereto and incorporated by reference herein.



 
     


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
  RITA Medical Systems, Inc.
 
 		  
 		  
 
Date: June 3, 2004 By:   /s/ Donald Stewart
 
Donald Stewart, Chief Financial Officer and Vice President Finance and Administration


 
     
 
RITA MEDICAL SYSTEMS, INC.

INDEX TO EXHIBITS


Exhibit Number
Description
99.1
Press Release of RITA Medical Systems, Inc. dated June 3, 2004.


 EX-99.1 2 ex99.htm Unassociated Document

Contact:  Allen & Caron Inc.
Jill Bertotti (investors)
949-474-4300
jill@allencaron.com
Surf Media Communications
Juliana Minsky (media)
805-962-3700		 RITA Medical Systems, Inc.
Don Stewart, Chief Financial Officer
Stephen Pedroff, Marketing Communications
650-314-3400
dstewart@ritamed.com
spedroff@ritamed.com
jm@surfmedia.com
         
 
RITA MEDICAL SYSTEMS TO PROVIDE EDUCATIONAL GRANT TO SUPPORT CONTINUING MEDICAL EDUCATION PROGRAM

Continuing Medical Education Program on Medscape Internet Site to Inform Medical Oncologists and Interventional Radiologists about Radiofrequency Ablation Treatment for Soft Tissue Cancer Tumors

MOUNTAIN VIEW, CA (June 3, 2004) . . . RITA Medical Systems, Inc. (Nasdaq: RITA) today announced the Company will provide to Medscape an unrestricted educational grant to support a live online continuing medical education program (CME). This CME program will educate medical oncologists and interventional radiologists about the use of radiofrequency ablation (RFA) treatment for soft tissue cancer tumors. The program will be archived for one year on Medscape’s web site and will also be available to patients as an information source for cancer treatment options.

Mr. Joseph DeVivo, President and CEO of RITA Medical Systems said, “We believe that an education program is the best way to inform medical oncologists and interventional radiologists about the use of radiofrequency ablation to treat cancerous and benign tumors.”

Scheduled faculty presenters for the education program include Peter Mueller, MD, Professor of Radiology, Harvard Medical School, Director of Abdominal Imaging an Interventional Radiology, Massachusetts General Hospital, and Lawrence S. Blaszkowsky, MD, Instructor in Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center.

RITA Medical will make available information about the education program during the upcoming American Society of Clinical Oncology (ASCO) annual meeting, June 5th through the 8th, in New Orleans, Louisiana. The CME program is scheduled to take place June 23, 2004 from 7:00 p.m. to 8:00 p.m. Eastern Time. Physicians may register for the event at www.medscape.com/cmelive/treatlivercancer.

About RITA Medical Systems, Inc.
 
RITA Medical Systems develops, manufactures and markets innovative products for patients with solid cancerous or benign tumors.

The statements in this news release related to the use of educational programs to inform physicians about the use of RFA to treat patients with cancerous or benign tumors, and the company’s expectations regarding the extension of its technology to applications beyond the liver are forward looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Information regarding these risks is included in RITA Medical’s filings with the Securities and Exchange Commission.

# # # #

 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#Q^[\3Z^MY M.HUS4P!(P`^UR>OUJ$>)_$)(`US5"3T`NY/\:NW7B1;>\F^PZ%HUJXD.7-NU MR3SW$[2#]*;#XN\4S2K;:?J5W;F4[5M]-'V=7)[!(@H/TQ0!H6]O\1;F%9H_ M^$D$#=)WDF2/_OMB%_6I?+\3P\W_`(TM[-/[S:YYY'_`8&D;]*KR^"-<.+SQ M'=VVC(ZE]^KW&V9@/2$;I2?^`TBCP7ID@2*+4_$=UOVJ"/L=NW'&`-TC\^\9 MH`N17X5UBF^(.M74SD*B:7!/-DGM^]>(_D#740V%];&+[?/XDL_,!\HZQKGV M5YFSC"VJ1O.V2>-O7UIL,.LZ1IJ7>NW]EX$TR1!MLM,M]FH72@]`,F7!((S( M^`<9&*['PYHT&CBWD32[G1%OG*6UOD2ZUJG=R\A_X]XR-I;;MVG)W)P2`=-X M1\&+(!=ZG'=%1@QI++LF\+^''BBU/;LO+BW;*VF>J(W&7Y.6 MXQ_O'Y?,_@H<_%W0R?\`IX_]$24`?7E97B#1#K^G+:#5=3TW$@D\[3IQ%(<` MC:6(/'/3V%:M%`'S3\6!XG\`:O916'C77KBTO(F=!/>-O0J0""1@$M6UM%`US,Z7;ER@95PN3@$EAR??K6_P#M*?\`(4\/_P#7 M&;_T):R?V<_^2A7_`/V"I/\`T;%0![-'\.)(F#+XY\8YQCYM11L_@8R*Q-?\ M-_$S1K5KGPSXQDU-8QDV=];1>8P`Z!RN&/UV_4FO4J*`/G;0OVB-6L[O[-XF MT:*:-&V2/:@Q2H0>>-](US4-,/BO4)39W,EN9!)C?L8KG';.*]>^&6C:[XO\(1ZWJOC;Q`DD M\KK'':3H@55.WG6-K_9>F16\MY<7(@3#7%TX:1P.[$`#]*^4]/U'QMX^\?:@?#6IZ MG;F\N'F)2[DBCMXB?EWE3P`N!ZG'`)KZA\3Z9=ZUX7U/2[*X2WN+NV>!99%) M"[A@]/8GGMUJGX+\&:9X(T)--TY-SG#7%PPP\[^I]!Z#L/Q)`.:L/A?JL4$: MW_Q$\4SR`?.8+ORP?INW'\R:N_\`"M'_`.AZ\:?^#-?_`(W7=44`?,7Q7O/$ M'@3Q3:Z7I?B_Q'-!+9)<,UU?LS!B[K@%0!C"#MZUI_"&/6OB`^L+JOC'Q-#] MB$)C^R:@5SOWYSN#9^Z/3O69^T9_R4*P_P"P5'_Z-EK=_9H_UWB;_=MO_:M` M'HW_``K1_P#H>O&G_@S7_P"-UE:Q\+_$$EC+_8_Q$\1QW."8UN[MF1O0$I@C MZ@'Z5Z?10!\J^%-=\4>%?B_IEKXIO-1>7S_LL\=WE?5 M5<9\0_AYI_CS20CE;?5(`3:7@'*G^ZWJI_3J/?KK99DM85N9%DG"*)'1=H9L MU-U-!"TB0!PAD(&=N3TS7R5XA^+/B;7O$UGK'VC M[*EC,);2TA)$<>/[W=R1P2>H)&`#BO??BEJUS*/#ECK5D?W-U&'VGJC=&4^X8$?A6K7S3\`/&@TK79?#-[*%M-1.^ MV+$`)<`=/^!J,?55`ZU]+4`%%%%`'QM"-(NYB+?4O$-R)&R9F^Q6W?G:I M:1L'_:2JTOC_`%Q87MM)-MH=LX`:+281`6Q_>D&9&_X$QK0MOAU?RK)JWB&\ M@\.Z.\C%;F_!\V49_P"64(^=ST/;(Y!-2MXRT+PL/*\#Z41=KUUO5%66XSZQ M1XV1=QG!)!YYH`ALOAY=):IJ_C#4H_#VGS$LINP7NKCGG9"/F/.,DXX(/(K5 MT?77;45T7X7>''BO)`0=3N@LUZR]"VX_)`OS8./;D&LOP]X-UOQW+W7`Z9S@'>F\6!S'X)^%6G3V\5TXCEO^EW?$`_,6 MXV)U;/&!_<&10!K6EO8^#-?2UL\>,OB/=2[=[L9(+*0=26)RS@CDD@@*2=F# MEWB_Q?)AX^4#T`&.N`;P M_P"'YHKOQ9S;Q+XIOSH_AU7W27D M_P#K;D]2(E.2Q//S8//0,010!S_AGPIK7C/5Q8Z3;-/*2#+,YQ'$"?O.W8=? MR_#K_`(0[PMX[TOPYHVS6]:N?-^V:Q_RS@VQ.WEPCO]WEAV)Y.<+Y MYXF^(JSZ2?#?A*S.B^'!D/&I_?79/!:5O<`#&3Z$D8`G^!]G=3_%32KF&VFD M@MQ,9Y40E8@T,@7<1P,G@9ZF@#ZVHHHH`^>/VE/^0IX?_P"N,W_H2US_`,`M M3L-*\=7T^HWUM9PMIDB"2XE6-2WFQ'&6(&<`\>U=!^TI_P`A3P__`-<9O_0E MK`^`&GV6I>.[Z&_L[>ZB&F2,$GB5U!\V(9P1UY/YT`?1+^-?"D:[G\3:,H]3 M?Q?_`!5DWFW$<]B@15..,QC"D>O`)]17S?XM\'Z]\.M?BBNB\;!O-L[ZV8A M9,'[RMU5@<9'4<'H02`:EGX$\=?$/79]3DTR>-KR0RR7EXIAB&?3(R5'0!0< M"OIGP+X+L?`OAN/2K1VFD+>;<7##!ED(`)QV&``!V`[G)/G?PE^,9UV6+P]X MEF1=2;Y;2\.%6X_V'[!_0]&Z=<;O::`"BBB@#X@\:?\`(]>(?^PG<_\`HUJ^ MF/@9_P`DIT[_`*ZS_P#HQJ^9_&G_`"/7B'_L)W/_`*-:OICX&?\`)*=._P"N ML_\`Z,:@#T>BBB@`HHHH`^8OVC/^2A6'_8*C_P#1LM;O[-'^N\3?[MM_[5K" M_:,_Y*%8?]@J/_T;+6[^S1_KO$W^[;?^U:`/H"BBB@`J"]O+?3K&XO;N416U MO&TLLAZ*JC)/Y"IZ\G^*M[=^*-:TOX;Z/,$FOV%QJ,P&X0P*<@$?ANQD'A!G MYJ`+?PPM;GQ%JFJ_$/4D99=38V^G1,?]3:(V`,9QDE1GCJI(^]78>,?#%MXP M\+7NBW.%\],Q2E<^5(.58?0]?49'>N5M/!/C^QLX+2U^(\<5O!&L44:Z%!A% M48`'/0`5-_PBGQ&_Z*8O_@C@_P`:`/E*ZMK_`$'69;:826NH64Y5MK8:.13U M!'H1D$?45]B_#SQ;'XU\&V>K?*+H#R;M%&`DR@;OP.0P]F%>%_&#X=Z_I4*> M*=2UI-9DE=8+J9+%;V"2#VPQ)Z"@#ZRHHHH`^%]:U#4M>^N;B^NY)2@:1B['GA1 M[>@''I7>:9X&T?P;I\.O?$-R))$WV>@1-^_G)Z&7^XO7(X]"1K?C`EA+J3KFWL68_,L8_B8#C/J3D]4KSG_B=^,O$@&;C4]7OI,#)W M.YQ^0``]@H'8"@#?USQ/XC^)>M6>D6=KLMMXCT_2+,;8H0!@<<#A.=141WEY;H7-L&Z11#&<],<9)PQ'W5&]HGAJX\$6 M4WA[PFD%[XSN80=5U=^+?2XFY"[B..F0N-S8W$8"J.<@U:V\/7LVA_#:WF\0 M>*+AB+S7WB\P]<-Y0.0%+'ER<>I;@@`HQ>&]"^'4:ZKXZV:MX@E/F6^A1RAP MO??<-R.3VY!_VN=O.7^H>,OBQX@55@GOYDSY5M;IMAME)[9.$'0;F/.!DFK\ M^B^'_#5U)>>--3DUO678N^E6%QN_>$Y/VBXYP<[@0N6S@YK/U'QGXA\2QIH& MCV@L--<[8M)TB$J)./XMOS2,0!G.OO^$@U->NF:9+MM MT/'$MQU/!/"#@C&:ZGX8^-]6USXHZ#IP\C3](0SE--L(_)@!\A^2!RYR,Y8G MGTKB%\!7MF!)XAU#3]!CPK>7>S;K@@^D$8:0?\"`'O7:_"<>$;3XF:1;:6=5 MU&_8W`6]N`EO"F(G.5B&YFR`1RPZ].*`/IJBBLS7;/5KZQ2+1M732[D2!FG> MT%P"F#E=I88Y(.?;WH`\+_:4_P"0IX>_ZXS?^A+63^SG_P`E"O\`_L%2?^C8 MJ[GQ+\$M:\7:@E]K?CHW,R)Y:?\`$J5%1Q!Z`]J`/:ZR/$OAK2_%NASZ3JT'FV\G*LO#Q..CH M>S#/\P<@D&MH&E^);"ZD?6O$L.JP&/"QKIJV[*V1\VX.,=^O%=!0!\2^ M,/"NH>!_$\VE7;$M&1);W"`J)8R?E<>G3UX((R<5]$_!_P")J^,-,&DZI(!K MEHG+$_\`'U&.-X_VA_$/Q'4@='\0?`-CX_T2.RN)OLMU`^^VNQ'O,><;AC(R M"!R,CD`]J\VM/V<[FPNXKJS\:RV]Q$VZ.6*P*LI]01+D4`>[T5RV@Z)XMTV[ MB;5O&$6K6JYWQ-I20NW!QAU?CG!Z'./?-)J^B^,+R[F?3O&-OIUNQ_=QC2%E M9!Z%FDP?RH`^2O&G_(]>(?\`L)W/_HUJ^F?@9_R2G3?^NL__`*,:N+F_9MEN M)Y)YO&+22R,7=WT[)9BN M#YN0.^,XS]30!Z;15;3XKN"PABO[I+JZ5<23I%Y0<^H7)Q^9JS0`445B:]IW MB"^:+^Q=?@TI5!\SS+`7!M`'S[^T9_R4*P_P"P5'_Z-EK=_9H_ MUOB;_=MO_:M:NO?`C5?$^JR:GK'CEKJ[=0I'M#O=7OG"6UI M$9'Y`+8Z*,]R<`#N2*\^^#VDW%[!J7CO5E!U37IF:///E6X;`5<\@$CID_*B M5#XE^%7BGQ=;I;:S\0GGMD?>L":2D:9]PL@W8[9SBK.@?#CQCX:T^/3]-^(K M+9QYV0RZ0D@7/8%I"0/8'%`'IU%-C#K$@D8.X`#,!@$]SCM3J`*&M:1::_HM MYI5_'OM;J(QN.XST(]"#@@]B!7Q-XAT.Z\-^(;[1KT8GM)3&3C`<=58>S`@C MV(K[#\1:+XIU*\231/%RZ-;B,*T/]F1W!9LG+;F88R".,=O>O,]5_9]OMY+'+ M.,?)(?J`02>I5J]#KQ;P_P#`O5_"VI?VAHOCM[2YV%"RZ8&#*>H*M(01T/(Z M@'M7KFD6U_::7#!J>H+J%XN[S+E8!"'RQ(^0$@8!`Z\XS0!\16^EWNL^(/[- MTVV>YN[B=DBBC').3^``'))X`!)XKZ:\*?#^R^''A=W\]G\07B[)[NVA\Z8# MO';(0>GJ1C^)AM4*-/X>_#NP\!:?/?7.R?6+D%KFY52VQ2<^7'QG;T]V/X`9 M'B_7]2U0R06EEJ:VN-AB^R7JEAWSY$0+=^DZ@@C*F@#F/%%Y9L#H-]+/#;>: M7C\+:$YN+RZDZYO)QN&XGEE!8\@Y8@&N6U6YUI=/;3)KK2/`NA$#=IT4I:ZE M4Y'[U8PTSMC@[]H.!FK-W'K2P2V]MI7C..T<\V.E:(-+B88QAF4R,_'=P37. M?V!>6_%I\+]7F'KJ0NI3_P"05B'Z4`98N_!NDY%KIU]KMP`P$M^_V6`'L?*C M)=A]9!]*D_X3#Q3JBMINC*;&WE/_`!XZ);>0&R-N&\L;WX_OEJT/LWCF(!;/ MP2]FHZ>5X>#L/H\D;/\`^/57N[+XFW\!M[JS\5S6Y_Y8M#<>6/HN,#\J`,@^ M#/$*-B[TYM//KJ4J6>?QF*YKMOA!HBV/Q2T>2?5],,Z^=MM89C,[YAD!PR*T M?&<\L.G&:XG_`(0CQ9_T*^M?^"^7_P")KM_A!X6\0Z;\4M&N[[0=4M;:/S]\ MT]G(B+F"0#+$8')`_&@#ZFK#\6^*;+P=X>FUJ_BGEMXF12D"@N2S`#&2!W]: MW*\U^.%O>WG@:VMK"UFN)I=1A!6*-G(`#'/'09`Y/%`%J#XO^'[C6-!TV.VO MS+K4,$=5TOQ59S-87C6MCXIAM8F$+$)!'*[%AQ]P[\YZ5V_QW MLKNYU;P=<6]IJ9[:S*QW"E[DX:/_`%@`R7[GWS6+\'M% MUB;QC?\`B:\TRZTZS_LJWTZ-+I"CRND<*EE!_A_?$K38/',?A2ST_4=0O%=%NI;2+?': M[R!ESGH-R[CT&>NV_QB\<7,]G<16\S#RI7C*J_S_P`)(P?PJAH+ MZAX!^+^OVM]HU]=VOB6]22TO;>/IQZUH:> MVHZA^SA-:W%GH,;+[E`',^#/B/9^-;EH[71]5LXC$TT%Q=PA8IT5@C;6!()#'!`SCUK.UGXQ M:'H6HZGI]]I^IK>V%S';^0L<9:?>&*L@W\KA0><'YEXKEO@PFHP>+M=ATVRU M:T\(F/?#!J*X,5QE?E7/I^\''4!=W.*N^+_#"7WQ]\*WQT^=[8PB2XF2,[!) M%O:,LP&,Y"#D\@`4`=MXP\=V'@RRL9+VTN[B[OY/*MK*V0/([8&1UQP2HXSR MPP#4A\:6Z^!W\4-I6J+$FX/9-`!O2N5^-\5G/X6@BNM&O[R M0F1K6[L5W/:S@#9N_P!ACP>>W`)`QTWPW?7'^'^E-XC$PU/RV#^?_K2NX["_ M?=MVYSSZ\YH`J^!_B7IGCVXN8]-T_4H%MUW-+^(VD^'?&>E^%[NVO'O-1$7E21*IC7S)#&NXE@>J]@:7P/\`$72? M'S:B-+MKR$6)C$AN54!M^[&W:Q_N'KCM7F'Q5TK5=3\>ZQ>V-E>/)IVC6[VL ML,#G,JW,;84XY(5V/'I[&M?X.:1>:#XKUBTFLKF"*;2]/DWRPLH,@A0NH)&, MAG8$=>/K0!U^G_%#2M4\93>'K/3M3E$-P;62_6$&W64;OE+9X!VD`]R.!CFN MXKP33%U*#X[L_AO2-5L(9KJ1=9BG0_99%#-^]4^C+\XST9L#(->M2^+;=/'D M'A.*TGFN7LS>2SH5\N&/)`WR6EPEI)IZJD[1,(V.(.`V,$ M\'\C0!LZI\6]"TG5]=TR>TU!KC1H1--L1,2*61?DR_)_>`\XX!K?N_&&EV'@ MB/Q9=F6+3WM8[I5*@R$2`%5P#C<2P'7&>^.:\!^(?A+6;_Q9XRUBRL[TM!<6 MZJJ0L1/#(A5]O'S88)TZ9)[5Z%XN\,ZIKO[/^CV-C;3/?6EC9S-:A<2/LB`9 M=O7(!)QU)7`&<4`=WX/\5)XOT8ZG'IE_81%]L:WD>PRJ5#!U]5(/7V-=!7(^ M"?%1U[P>;XZ-?V73Y=/ M>XWYMI3EDVNR\\#KMST[T`;5%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`50MM$TZTUF]U>"U5;^]5%N >)\DEP@PHY.`,>F,]Z**`+]%%%`!1110`4444`?_9 ` end -----END PRIVACY-ENHANCED MESSAGE-----